China CRO Company,Preclinical research services


About Us

Executive Team

Location:Home > Executive Team

  • Chunlin Chen, Ph.D. CEO

    Formally a Staff Investigator for Vertex Pharmaceuticals, Dr. Chen co-founded Medicilon in 2004. Dr Chen is a highly published thought leader in the pharmaceutical industry with extensive experience in academia, pharmaceutical, and regulatory evaluation. Dr. Chen received his PhD from Oklahoma State University and completed postdoctoral training in the United States. He is a Postdoctoral Fellow at the St. Jude Children’s Research Hospital and has held numerous leadership positions in professional scientific trade organizations in China as well as other parts of the world. Dr. Chen has been awarded as special expert under national "Thousand Plan" program.

  • Guolin Wang, MBA, Board Secretary

    Mr. Wang holds a masters degree in business administration from the open university of Hong Kong. Before joining Shanghai Medicilon Inc. in 2008, Mr. Wang has 9 years of middle and senior level management experience in China Telecom, a large-scale state-owned enterprise, and 6 years of senior management experience in China Unicom, a listed company at home and abroad, as well as 3 years of senior management experience in investment management and health care industry. He served as Deputy General Manager in the municipal branch of China Telecom and China Unicom. He also served as General Manager in a health care investment company. He has rich experience on management and investment.

  • Xingchu Gu,Ph.D. VP, Preclinical Research/Test Facility Manager

    Dr. Gu was Director of the Toxicology Research Department at the Shanghai Institute of Pharmaceutical Industry – China and Executive Director of the National Shanghai Center for New Drug Safety Evaluation and Research – China. He is the GLP expert of the China State Food and Drug Administration. Dr. Gu was a visiting scholar in the German Houchst Pharmaceutical Company where he did drug preclinical research for two years. He also did short-term visits to GLP laboratories in United States, Canada and Australia. Dr. Gu was the project leader of 973 national projects and a total of 7 projects granted by National Youth New Drug Fund and the Science and Technology Commission of Shanghai Municipality-China. Dr. Gu also received the second prize for Science and Technology Advancement awarded by the Shanghai Municipality-China. He is the member of CFDA, GLP expert group and Chinese Society of Toxicology.

  • Jun Wang, Ph.D. VP of Discovery Biology

    Dr. Jun Wang, VP of Discovery Biology at Shanghai Medicilon Inc. Before joining Medicilon, Dr. Wang was the VP and Head of Biology at Sundia MediTech. Dr. Wang served at Merck & Co., Inc. for 9 years, leading multiple drug-discovery programs on principles of food-animal growth promotion, infectious diseases, diabetics and cardiovascular diseases. Prior to Merck, Dr. Wang worked at a biotech company in Seattle as the head of biology section and served as an assistant professor in University of Texas Southwestern Medical Center and University of Washington for 5 years. Dr. Wang has been invited by many corresponding author in leading scientific journals. Lately, Dr. Wang has been invited by many organizations including University of Cambridge, Royal Society of Chemistry, and Naito Foundation for presentations on his discovery of novel candidates of antibiotics (Platensimycin and Platencin). Dr. Wang got his BS in biophysics from Fudan University and received his Ph.D. in molecular biology and biochemistry from Kobe University (Japan). He had his post-doc training in the Department of Pharmacology at UT Southwestern Medical Center (Dallas).

  • Huanming Chen, Ph.D. VP of Chemistry

    Dr. Chen obtained his Ph.D in Medicinal Chemistry from China Pharmaceutical University. Dr. Chen joined Shanghai Medicilon on Aug 2013. Before joining Medicilon, Dr. Chen was the Head of Shanghai R&D Center at Simcere Pharmaceutical Group. Prior to Simcere, Dr. Chen worked at BioDuro as a Senior Director of Medicinal Chemistry. Dr. Chen has extensive experience in leading drug discovery projects including key intellectual property development, hit-to-lead-to-candidate development, rational and structure-based drug design, optimization of ADMET and pharmacological properties of preclinical drug candidates and top-performing team management. Dr. Chen also served at Valeant and Ardea Biosciences as Senior Principal Scientist before joining Medicilon.

  • Guodong Li, Ph.D. VP of CMC

    Dr. Li obtained his Ph.D. in Pharmacy from The Second Military Medical University. After obtaining his Ph.D., Dr. Li worked in College of Pharmacy at The Second Military Medical University as a Senior Professor for 20 years. Besides teaching in the University, Dr. Li also worked as a researcher on the pharmaceutical product development. After 20 years of teaching and before joining Medicilon, Dr. Li was the VP and Chief Engineer of BioAsia Pharmaceutical. Dr. Li has an extensive experience in pharmacy. He has published more than 40 scientific research papers. As an editor, 5 monographs have been edited by Dr. Li. In addition, Dr. Li has participated in the “863 Project”. In 2008, Dr. Li received “The Third Class Military Award”. Dr. Li joined Medicilon in 2014.

  • Lu Chuan Shu, Ph.D. VP of Pharmaceutical Analysis Department

    Dr. Shu graduated from Jilin University in China and received his Ph.D in Chemistry from Iowa State University. Dr. Shu has 18 years of technical and managerial experience from major US pharmaceutical companies. Dr. Shu also has extensive experience from CRO in China. Dr. Shu is a drug analysis research and development experts. Dr. Shu’s scope of analysis includes pharmaceutical raw materials, excipients and preparations (solid, oral liquid, injection liquid, aerosol, colloid, emulsion and others). The expertise of Dr. Shu covers a wide range of pharmaceutical analysis areas including development, validation, transfer, standard characterization studies and standardization of analytical method, formal stability studies and clinical trial drug quality control testing and release. Dr. Shu is familiar with GMP, ICH, pharmacopoeia of US and Europe. A lot of Dr. Shu’s research projects have been approved by the government and launched to the market.

  • Jinna Cai, Ph.D. VP of Business Development

    Dr. Cai completed her whole high-level education in China Pharmaceutical University from Bachelor to Ph.D. Her doctoral research is cooperative with Institution of Natural Medicine of University of Toyama. Later, she worked in Postdoctoral workstation of Shanghai Institution of Meteria Medica. She contributes herself to new drug development and research for over twenty years. Her research on a Chinese Traditional medicine named Fructus Cnidii was awarded the first award for Science and Technology Progress by State Administration of Traditional Chinese Medicine in 1991 and National Awards for Science and Technology Grade I in 1992. She has served in Huiren Group as director of R&D Center for 5 years in charge of new drug development and application, most of which has been approved. Thereafter, she mastered the whole procedure of new drug application. She was awarded one of the top 10 employees by Huiren Group and Excellent Management Individual of Provincial Technological Center during the “10th –five-year “by Jiangxi Province. Dr. Cai joined Medicilon in July 2008.

  • Peter H Rehse, Ph.D., VP of Business Development in UK

    Peter Hugo Rehse, as Vice President of Medicilon since 2007, has more than twenty year experience as a scientist specializing in macromolecular crystallography and analysis. He received his bachelor and master degree in Canada and received his Ph.D. in Crystallography from the University of London, England. Dr. Rehse communicates with English, German, French, and Japanese. His projects have ranged from basic science to direct applications to the pharmaceutical industry conducted in internationally acclaimed facilities and institutes in Germany (Max Plank), Canada (NRC) and Japan (RIKEN), which the RIKEN Protein 3000 project solving a large number of crystal structures. Just before joining Medicilon, he worked as a Visiting Scientist of Structural Biology in Intstitute of Biochemistry and Cell Biology, Chinese Academy of Sciences, Shanghai, China. He joined Medicilon at the end of 2007, in charge of structural biology.

  • Mingzhu Zhang Ph.D, VP of Business Development in US

    Dr. Mingzhu Zhang resides in San Diego, California, USA and she is responsible for business development in U.S. on behalf of Medicilon. Dr. Zhang holds a Ph.D. degree in organic chemistry from Shanghai Institute of Organic Chemistry (SIOC) and was a post-doctoral fellow in The Scripps Research Institute (TSRI) and Vanderbilt University. She has over three years postdoctoral experiences, one year CRO, over seven years experience in pharmaceutical industry including DuPont Pharmaceuticals and Neurocrine Biosciences and over 8 years of business development with Medicilon. Her broad background includes: medicinal chemistry (CNS and oncology), custom synthesis, peptide chemistry, nucleoside and nucleotide chemistry. In addition, Dr. Zhang is the president of San Diego SABPA, a volunteer based non-profit professional organization. Dr. Zhang has a great combined talent in drug discovery and business development.